Astra pulls further ahead of Merck’s Curon project
A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.
Lyell takes on J&J and Gilead
The players are vying in the CD19 x CD20 Car-T arena.
Galapagos split stutters
The group’s point-of-care Car-T push looks to have stalled.
Crispr’s Car-T crunch time
The group could soon provide clarity on CTX112’s regulatory path.
Make or break time for Caribou
The company’s matching strategy for CB-010 will soon be put to the test.
AstraZeneca doubles down on GPC3
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
